Trial reportJournal of psychopharmacology (Oxford, England)2025
Acute effects of 150 mg caffeine on subjective, physiological, and behavioral components of anxiety in panic disorder and healthy controls - A randomized placebo-controlled crossover trial.
Trial report in Journal of psychopharmacology (Oxford, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCaffeine in doses above 400 mg, approximately four cups of coffee, induces panic attacks in 50% of individuals with panic disorder (PD) and elevates anxiety, but it is not known how individuals with PD respond to normally consumed doses or how caffeine interacts with emotional tasks.
aimsWe hypothesized that 150 mg caffeine would increase subjective anxiety (primary outcome) as well as interoceptive attention and anxiety from bodily signals in patients with PD, and more so than in healthy controls (HCs). Additional analyses targeted panic attacks, emotional reactivity, avoidance behavior, and subjective exteroceptive attention.
methodsTwenty-nine patients with PD and 53 HC with low habitual caffeine consumption (⩽300 mg/week) abstained from caffeine 36 h before receiving 150 mg caffeine or placebo in a double-blind randomized crossover design 2-14 days apart.
resultsContrary to our hypotheses, caffeine did not increase subjective anxiety, interoceptive attention, or anxiety from interoceptive signals. Only one panic attack was noted, in the PD group after caffeine intake during the emotional reactivity task. In both PD and HC, caffeine increased skin conductance responses to neutral and emotional faces, augmented costly avoidance behavior, and impaired exteroceptive attention. These results indicate that low caffeine doses do not have differential anxiogenic effects in patients with PD and HC at rest, and that they increase arousal and avoidance behavior in both PD and healthy individuals.
conclusionsIn conclusion, we suggest that recommendations for caffeine abstinence for patients with PD should be based on higher doses and ideally on individual assessments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.